Women (n =179) | Men (n =86) | Total (n = 265) | Excluded, did not complete 6 months (n =47) | |
---|---|---|---|---|
Age, y | 31.0 ±8.0 | 38.0 ±9.0 | 33.0 ±8.8 | 32.2 |
Body mass index (BMI), kg/m2 | 19.6 ±2.5 | 19.1 ±1.8 | 19.4 ±2.3 | 19.5 ±2.5 |
CD4 count at enrollment, cells/ul | 189 ±113 | 194 ±113 | 190.7 ±113 | 181 ±105 |
Viral load, log(copies/mL ) | 4.7 ±1.0 | 4.6 ±0.9 | 4.7 ±1.0 | 4.8 ±0.9 |
WHO stage | ||||
Stage I | 63 (35.2) | 23 (26.7) | 86 (32.5) | 11 (23.4) |
Stage II | 47 (26.3) | 32 (37.2) | 79 (29.8) | 12 (25.5) |
Stage III | 53 (29.6) | 26 (30.2) | 79 (29.8) | 19 (40.4) |
Stage IV | 16 (8.9) | 5 (5.8 ) | 21 (7.9) | 5 (10.6) |
ART regimen | ||||
TDF/3TC/EFV | 113 (63.1) | 77 (89.5) | 190 (71.7) | 33 (70.2) |
AZT/3TC/EFV | 2 (1.1) | 1 (1.2) | 3 (1.1) | 1 (2.1) |
TDF/3TC/NVP | 27 (15.1) | 2 (2.3) | 29 (10.9) | 3 (5.7) |
AZT/3TC/NVP | 31 (17.3) | 4 (4.7) | 35 (13.2) | 10 (18.9) |
Other* | 6 (3.4) | 2 (2.3) | 8 (3.0) | 0 (0.0) |